This research study is enrolling adults
who have been prescribed vimseltinib (ROMVIMZA™) to treat tenosynovial giant cell tumor (TGCT).
This condition can damage the soft tissue of the joint called the synovium. TGCT is a locally aggressive non-malignant tumor. Symptoms include joint stiffness, pain/swelling, and limited range of motion that can affect mobility and physical function.
888-581-9246
A Real-World Study for Adults on Vimseltinib for TGCT is Enrolling.
This research study is enrolling adults who have been prescribed vimseltinib (ROMVIMZA™) to treat tenosynovial giant cell tumor (TGCT).
This condition can damage the soft tissue of the joint called the synovium. TGCT is a locally aggressive non-malignant tumor. Symptoms include joint stiffness, pain/swelling, and limited range of motion that can affect mobility and physical function.
The main goals of the study
are to learn about people’s experience while taking vimseltinib for TGCT in
real world settings.
are to learn about people’s experience while taking vimseltinib for TGCT in
real world settings.
To qualify you must:
• Have a diagnosis of TGCT
• Have been prescribed vimseltinib
Those who qualify and enroll may receive:
• Compensation for their time
NOTE: Since this is an observational study only, vimseltinib will not be provided to you (or paid for) by the study sponsor; nor will the sponsor pay for any of your healthcare costs.
What do researchers want to learn?
Vimseltinib received FDA approval in early 2025 to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery may make the symptoms worse or cause severe problems.
Vimseltinib was approved because it was shown to be effective in a clinical trial, the MOTION study. However, there is now a need to understand real-world use of the drug, such as how/when it is prescribed and how well those taking it tolerate the treatment in clinical practice.
This study was designed to explore prescribing habits as well as patient satisfaction with the treatment.
Researchers also want to assess what proportion of those prescribed vimseltinib for TGCT continue to take it and for how long and, for those who stop taking it, why they stopped. The real-world data that is collected will be entered into a database for further analysis so researchers can understand how the drug used.
Know that even if you volunteer, qualify and enroll, you can still withdraw from the study at any time, for any reason.
Act now to see if you may qualify.
How do I start?
Answer some
questions
about your health
questions
about your health
Tell us a little bit
about you
about you
Connect to a virtual
study site to see
if you qualify
study site to see
if you qualify
Just takes a few minutes.
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
*For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary. For patients in the United States only.
Terms of Use | Privacy Policy
Privacy Policy | Deciphera
©2025 Acurian, Inc. All rights reserved.
DCPH-M00825